Rheumatiod arthritis: Preventative treatment
Rheumatoid arthritis (sometimes called “RA”) is a common chronic inflammatory disease that affects around 1% of the population. It is 2-3 times more common in women. In most cases, patients begin having symptoms between 40 to 60 years of age, but it can begin earlier, or later in life.
RA affects the joints and causes pain, swelling, and stiffness, but also fatigue. If patients are not treated, the joints can suffer permanent damage, which subsequently can lead to disability. To date, there is no cure, which means that for the vast majority of patients treatments are long term, with the aim of controlling the inflammatory disease activity and reducing symptoms.
There is increasing research interest in the idea of treating individuals who are at an increased risk of developing RA to assess whether a relatively short course of therapy will prevent or delay the onset of RA. One such ‘at risk’ group are the siblings and children of patients with RA, who are four times more likely to develop the disease. The presence of RA-related autoantibodies in the blood increases the risk of developing the disease further.
This PREFER case study will ask siblings, children and members of the general public about their preferences for preventive treatments for RA. The case study will further look at how participant characteristics, country (UK vs Germany), population (siblings and children vs. general population), knowledge/experience with RA will impact on these treatment preferences. In addition, this case study will evaluate the similarity of two different methods to measure treatment preferences.
|Therapeutic area||Rheumatoid arthritis|
|Study led by||University of Birmingham
University of Erlangen
|PREFER leads team||Karim Raza
|MPLC decision points of interest||Early-development and post-marketing|
|PREFER case study acronym||RA|
|Clinical objectives||Assessing the preferences of people at risk of RA for preventive treatments
Evaluating the maximum acceptable risk (MAR)/Minimum acceptable benefit (MAB)
Characterising preference heterogeneity and characteristics that may explain heterogeneity
|Patients from||United Kingdom
|Methods in Qualitative study||Focus group discussion
Nominal group technique
|Methods in Quantitative study||DCE
Probabilistic Threshold Technique
|End-date qualitative data collection||December 2019|
|End-date quantitative data collection||Q3 2020|
Karim Raza, lead for Rheumatoid Arthritis case study
Karim Raza is Professor of Clinical Rheumatology at the University of Birmingham and Honorary Consultant Rheumatologist and Director of Research and Development at Sandwell and West Birmingham Hospitals NHS Trust. His research focuses on early rheumatoid arthritis, addressing pathogenic mechanisms, biomarker development, strategies to enhance clinical outcomes for patients with a new onset of disease and patient perspectives on disease and treatment. Specifically Karim is interested in:  Mechanisms driving the molecular basis for the switch to disease persistence and the timing of this switch in early arthritis.  Predictors of outcome in patients with early inflammatory arthritis and patients’ perspectives on predictive testing and preventive treatments.  Management pathways for patients with early rheumatoid arthritis, including the development of strategies to facilitate rapid patient assessment. Karim is an active proponent of patient and public involvement in research and has coordinated the establishment of the Birmingham Rheumatology Patient Research Partnership
Jorien Veldwijk, public co-lead for case studies
Jorien Veldwijk is a senior research fellow at the Erasmus Medical Center. Dr. Veldwijk’s research mainly covers measuring patients’ decision-making within a broad range of health care and public health topics as well as methodological issues. She is involved as a DCE expert in several studies in different organisations and countries, combining applied and methodological research which has resulted in publications in high-impact journals.